Drug Trial Radar · NCT05902169
Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM
Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
560
Planned (sponsor's estimate)
Start
Jan 29, 2024
Primary completion
Jan 28, 2028
Study completion Jun 30, 2028
Sponsor
- Lead sponsor
- CarTheraIndustry
- Sponsor type
- Industry
- First posted
- Jun 13, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The brain is protected from any toxic or inflammatory molecule by the blood-brain barrier (BBB). This physical barrier is located at the level of the blood vessel walls. Because of these barrier properties, the blood vessels are also impermeable to the passage of therapeutic molecules from the blood to the brain. The development of effective treatments against glioblastoma is thus limited due to the BBB that prevents most drugs injected in the bloodstream from getting into brain tissue where the tumour is seated. The SonoCloud-9 (SC9) is an investigational device using ultrasound technology and specially developed to open the BBB in the area of and surrounding the tumour. The transient opening of the BBB allows more drugs to reach the brain tumour tissue. Carboplatin is a chemotherapy that is approved to treat different cancer types alone or in combination with other drugs, and has been used in the treatment of glioblastoma. Despite its proven efficacy in the laboratory on glioblastoma cells, carboplatin does not readily cross the BBB in humans. A clinical trial has shown that in combination with the SonoCloud-9, more carboplatin can reach the brain tumour tissue. The objective of the proposed trial is to show that the association - carboplatin with the SonoCloud-9 - will increase efficacy of the drug in patients with recurrent glioblastoma.
Conditions
- Glioblastoma
- Recurrent Glioblastoma
- GBM
Interventions
SonoCloud-9 (SC9)Device
Implantation of SC9 device and repeat activation at constant acoustic pressure
CarboplatinDrug
Dose of carboplatin AUC 5 mg/ml.min-1 calculated using Calvert's formula: Dose (mg) = target AUC (mg/mL x minute) x \[glomerular filtration rate (GFR) mL/minute + 25\].
LomustineDrug
Dosed and administered per labelling.
TemozolomideDrug
Dosed and administered per labelling.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall survival (OS)Time frame: Up to 24 months
Locations
56 sites in 11 countries. Site status is shown where the registry gives one.
Mayo Clinic Arizona
Phoenix, Arizona
Kaiser Permanente
Los Angeles, California
UCLA
Los Angeles, California
Sutter Health - California Pacific Medical Center
San Francisco, California
University of California, San Francisco
San Francisco, California
UCHealth
Aurora, Colorado
Mayo Clinic of Jacksonville Florida
Jacksonville, Florida
Miami Cancer Institute
Miami, Florida
Moffitt Cancer Center
Tampa, Florida
Winship Cancer Institute at Emory University
Atlanta, Georgia
Northwestern University
Chicago, Illinois
Indiana University Health
Indianapolis, Indiana
John Hopkins University
Baltimore, Maryland
Mayo Clinic Rochester
Rochester, Minnesota
Weill Cornell Medicine
New York, New York
NewYork-Presbyterian / Columbia University Irving Medical Center
New York, New York
Lennox Hill Hospital
New York, New York
University of North Carolina
Chapel Hill, North Carolina
Neurological Institute Brain Tumor Centre Taussig Cancer Cente
Cleveland, Ohio
Penn State Health Milton S. Hershey Medical Center
Hershey, Pennsylvania
University of Texas Southwestern Medical Center
Dallas, Texas
University of Texas Houston Health Science Center
Houston, Texas
University of Utah, Hunstman Cancer Institute
Salt Lake City, Utah
Medizinische Universitaet Innsbruck
Innsbruck, Austria
Universitair Ziekenhuis Brussel
Brussels, Belgium
Universitair Ziekenhuis Leuven
Leuven, Belgium
CHU de Liège
Liège, Belgium
Rigshospitalet
Copenhagen, Denmark
Odense University Hospital
Odense, Denmark
Hôpital Neurologique Pierre Wertheimer
Bron, France
Hôpital de La Timone
Marseille, France
Hôpital de la Pitié-Salpêtrière
Paris, France
Hôpital Foch
Suresnes, France
Charité Universitätsmedizin Berlin
Berlin, Germany
Klinikum Chemnitz gGmbH
Chemnitz, Germany
Neurochirurgie uniklinik Köln
Cologne, Germany
Universitätsklinikum Carl Gustav Carus Dresden
Dresden, Germany
Universitätsklinikum Essen Klinik für Neurologie
Essen, Germany
University Hospital Munster
Münster, Germany
Ospedale Bellaria
Bologna, Italy
Showing 40 of 56 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.